Cargando…

CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity

AIM: The aim of this study was to investigate the expression of CARS (cysteinyl-tRNA synthetase) in clear cell renal cell carcinoma (ccRCC) and its biological action mechanisms. METHODS: Expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) to estimate the CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Quan, Li, Can-Xuan, Long, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274832/
https://www.ncbi.nlm.nih.gov/pubmed/34262333
http://dx.doi.org/10.2147/IJGM.S318278
_version_ 1783721611240669184
author Meng, Quan
Li, Can-Xuan
Long, Dan
author_facet Meng, Quan
Li, Can-Xuan
Long, Dan
author_sort Meng, Quan
collection PubMed
description AIM: The aim of this study was to investigate the expression of CARS (cysteinyl-tRNA synthetase) in clear cell renal cell carcinoma (ccRCC) and its biological action mechanisms. METHODS: Expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) to estimate the CARS expression patterns in ccRCC, its relationship with clinicopathological variables, and prognosis of ccRCC and potential biological mechanisms in ccRCC. RESULTS: CARS was significantly elevated in ccRCC. Overexpression of CARS indicated disease progression. Univariate and multivariate Cox regression analyses identified CARS as an independent prognostic factor for overall survival (OS) in renal clear cell carcinoma. Mechanically, CARS influenced the progression of ccRCC through several tumor-related pathways. Additionally, we found that CARS was significantly associated with tumor mutational burden, tumor-infiltrating immune cells, immunosuppressive molecules, methyltransferases, and mismatch repair proteins. CONCLUSION: CARS could serve as a promising prognostic biomarker and therapeutic target for ccRCC.
format Online
Article
Text
id pubmed-8274832
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82748322021-07-13 CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity Meng, Quan Li, Can-Xuan Long, Dan Int J Gen Med Original Research AIM: The aim of this study was to investigate the expression of CARS (cysteinyl-tRNA synthetase) in clear cell renal cell carcinoma (ccRCC) and its biological action mechanisms. METHODS: Expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) to estimate the CARS expression patterns in ccRCC, its relationship with clinicopathological variables, and prognosis of ccRCC and potential biological mechanisms in ccRCC. RESULTS: CARS was significantly elevated in ccRCC. Overexpression of CARS indicated disease progression. Univariate and multivariate Cox regression analyses identified CARS as an independent prognostic factor for overall survival (OS) in renal clear cell carcinoma. Mechanically, CARS influenced the progression of ccRCC through several tumor-related pathways. Additionally, we found that CARS was significantly associated with tumor mutational burden, tumor-infiltrating immune cells, immunosuppressive molecules, methyltransferases, and mismatch repair proteins. CONCLUSION: CARS could serve as a promising prognostic biomarker and therapeutic target for ccRCC. Dove 2021-07-06 /pmc/articles/PMC8274832/ /pubmed/34262333 http://dx.doi.org/10.2147/IJGM.S318278 Text en © 2021 Meng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Meng, Quan
Li, Can-Xuan
Long, Dan
CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
title CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
title_full CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
title_fullStr CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
title_full_unstemmed CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
title_short CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity
title_sort cars as a prognosis factor in clear cell renal cell carcinoma and its association with tumor immunity
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274832/
https://www.ncbi.nlm.nih.gov/pubmed/34262333
http://dx.doi.org/10.2147/IJGM.S318278
work_keys_str_mv AT mengquan carsasaprognosisfactorinclearcellrenalcellcarcinomaanditsassociationwithtumorimmunity
AT licanxuan carsasaprognosisfactorinclearcellrenalcellcarcinomaanditsassociationwithtumorimmunity
AT longdan carsasaprognosisfactorinclearcellrenalcellcarcinomaanditsassociationwithtumorimmunity